	US 12,029,733 B2
	Treatment of sepsis and related inflammatory conditions by local neuromodulation of the autonomic nervous system
Corinne Bright, Los Altos Hills, CA (US); Kondapavulur T. Venkateswara-Rao, San Jose, CA (US); and Emily Stein, San Jose, CA (US)
Assigned to Tulavi Therapeutics, Inc., Los Gatos, CA (US)
Filed by Tulavi Therapeutics, Inc., Los Gatos, CA (US)
Filed on Oct. 20, 2021, as Appl. No. 17/506,354.
Application 17/506,354 is a continuation of application No. 16/313,856, granted, now 11,154,547, previously published as PCT/US2017/040074, filed on Jun. 29, 2017.
Claims priority of provisional application 62/355,889, filed on Jun. 29, 2016.
Prior Publication US 2022/0280497 A1, Sep. 8, 2022
Int. Cl. A61K 31/455 (2006.01); A61K 9/00 (2006.01); A61L 27/52 (2006.01); A61P 29/00 (2006.01)

CPC A61K 31/455 (2013.01) [A61K 9/0024 (2013.01); A61L 27/52 (2013.01); A61P 29/00 (2018.01); A61L 2400/06 (2013.01)]

8 Claims

1. A method of modulating hypertension, the method comprising: positioning a catheter percutaneously within a blood vessel directly proximate to a nerve target site accessible from a pulmonary artery, the nerve target site being outside the blood vessel; and delivering a therapeutic agent to the nerve target site outside the blood vessel from the pulmonary artery, the therapeutic agent is amitriptyline or other neuromodulatory drug, wherein the therapeutic agent is delivered as an injectable in situ forming hydrogel slurry being configured to limit spread of the hydrogel beyond the nerve target site.